Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2010
08/25/2010CN101401816B Method for preparing Calcium polycarbophil particle
08/25/2010CN101375850B Application of norisoboldine in preparing medicament for treating autoimmune disease
08/25/2010CN101361714B Vincristine-reversal agent composite nano-granule and preparation method and use thereof
08/25/2010CN101361713B Curcumin nano crystallization preparation and preparation method thereof
08/25/2010CN101336895B Novel alkalized solid-liquid two-state skin quick-anaesthesia nano-emulsion and preparation method thereof
08/25/2010CN101327233B Compound external-use formulation for treating gonorrhoea and nongonococcal urethritis
08/25/2010CN101323600B Triadimefon and triadimenol compounds having antimicrobial activity, salts, synthetic methods and uses thereof
08/25/2010CN101322700B Applications of naringenin and naringin as signal pathway inhibitor of transforming growth factor-beta 1
08/25/2010CN101297809B Preparation of cefoperazone and sulbactam sodium mixed powder
08/25/2010CN101289440B Polyene macrocyclic compounds, preparation thereof and applications
08/25/2010CN101284104B Attapulgite delousing powder
08/25/2010CN101283996B Application of clock wise D-methionine in preparing the medicine for preventing and curing the myelosuppression induced by radiation
08/25/2010CN101279064B Attapulgite alcohol group delousing preparation
08/25/2010CN101264304B Chinese medicine capsule for treating intractable aypnia
08/25/2010CN101249214B Xiabing arrowhead spray for curing various pain
08/25/2010CN101219191B Medicament for preventing and controlling atony of proventriculus of ruminant
08/25/2010CN101212963B The use of chlorogenic acid in the manufacture of medicaments for increasing the effect of bone marrow cells
08/25/2010CN101210011B Quinolines compounds and their intermediates, preparation method and application
08/25/2010CN101181474B Chinese medicine ointment for curing skin diseases as well as producing and detecting method thereof
08/25/2010CN101164537B High-efficient oral silibinin sustained-release preparation and preparation method thereof
08/25/2010CN101157652B Antitumor activity bipyridine methyl amine compound and preparation method thereof
08/25/2010CN101143845B Substituted quinoline formyl guanidine derivative, its preparation method and medical use
08/25/2010CN101138560B Nitrofuran gelling agent and method of preparing the same
08/25/2010CN101138558B Pentamidine and death domain receptor ligand united application
08/25/2010CN101099729B Oral solid preparation containing ambroxol hydrochloride and salbutamol active components
08/25/2010CN101092420B (1Z, 4Z, 5Z) - 6 N isopropyl - 6 - aza -2 - oxo - 3 - oxa - 4 - methoxy - dicyclo [3, 1, 0] hexane and preparation method
08/25/2010CN101087791B Method for producing L-biopterin
08/25/2010CN101085310B Traditional Chinese medicine ointment for treating cow mastitis and method for preparing same
08/25/2010CN101084944B Composition for prophylaxis or treatment of urinary system infection
08/25/2010CN101066261B Application of dryopteris fragrans phloroglucinol extract
08/25/2010CN101065119B Ameliorant for renal insufficiency
08/25/2010CN101054375B Compound capable of inhibiting tubercle bacillus growth and application thereof
08/25/2010CN101044902B Health-care product for reducing weight and lowering cholesterin content in blood
08/25/2010CN101041626B Tetrafluorobenzyl derivatives and pharmaceutical composition containing same
08/25/2010CN101041076B Controlled ointment compound stroma and the preparing method
08/25/2010CN101002947B Target medicine used for treating bacteriosis, and its preparing method
08/25/2010CA2694683A1 Pharmaceutical compounds
08/25/2010CA2694679A1 Pharmaceutical compositions
08/25/2010CA2694672A1 Pharmaceutical compounds
08/24/2010USRE41571 drug delivery at least two-day additional dosing interval; allows for reduced plasma concentrations over a prolonged time period while still providing effective pain management; transdermal delivery system maximizes the dosage interval; FDA Orange book listed patent
08/24/2010US7781613 Inhibitor of hormone sensitive lipase; non-insulin dependent diabetes; antidiabetic agents; obesity
08/24/2010US7781596 Substituted 2-phenylbenzimidazoles, the production thereof and their use
08/24/2010US7781595 Benzimidazole derivatives: preparation and pharmaceutical applications
08/24/2010US7781594 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
08/24/2010US7781587 antitumor; breast cancer; 8,9-Dimethoxy-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one
08/24/2010US7781584 2-(6-Chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-benzonitrile
08/24/2010US7781577 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents
08/24/2010US7781575 siRNA targeting tumor protein 53 (p53)
08/24/2010US7781572 Nanosized carotenoid cyclodextrin complexes
08/24/2010US7781570 antibody produced in response to the derivative; effective tool in the guidance is the monitoring of aminoglycoside concentration in the biological fluid of a treated patient
08/24/2010US7781566 Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors; for preventing, treating, and diagnosing mammalian cancer tumors
08/24/2010US7781489 Microemulsions of retinoids, and pharmaceutical compositions containing them
08/24/2010US7781487 N-(1-cyanocyclopropyl)-4,4-difluoro-2(S)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino)octamide; rheumatoid arthritis, multiple sclerosis, myasthenia gravis, psoriasis, pemphigus vulgaris, Graves' disease, myasthenia gravis, lupus, asthma, pain, atherosclerosis; cathepsins B, K, L, F, and S inhibitors
08/24/2010US7781486 acupuncture pain relief with electrical current to needle electrodes stuck into sensitive points; intravenous infusion of a substance that inhibits enzymatic decomposition of endogenous opioid neuropeptides, (enkephalins and endorphins); e.g. D-phenylalanine and D-leucine
08/24/2010US7781485 Hsp90 family protein inhibitors
08/24/2010US7781484 crosslinked thiol ester oligomers having polysulfide linkages, formed by oxidation of thiol esters in the presence of amine catalysts; chemical intermediates for polythiourethanes used in fertilizers and fertilizer coatings
08/24/2010US7781483 Benzopyran compound
08/24/2010US7781482 pyrolidone derivatives useful in the treatment of vision defects such as such as post-operative gaucoma, ocular hypertensive episodes, glaucoma, presurgical adjuncts or increased intraocular pressure
08/24/2010US7781480 Serine, threonine kinase inhibitor ; apoptosis in animal cells; anticancer agents; cardiovascular disorders; rheumatic disorders; skin disorders; vision defects; urogenital disorders; central nervous system disorders; infections
08/24/2010US7781479 Antidiabetic agents; controlling blood sugar; stimulate peroxisome proliferator activator receptor
08/24/2010US7781478 treatment of viral diseases or affecting viral internal ribosome entry site (IRES) activity, comprisng administering 3-nitilo-indole derivatives
08/24/2010US7781477 Therapeutic use of N-(1H-Indolyl)-1H-indole-2-carboxamide derivatives
08/24/2010US7781476 Serotonin and melatonergic ligands such as 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide, used for the treatment of psychological disorders, side effect reduction of antipsychotic drugs, neurodegenerative disorders, chemotherapy-induced vomiting and eating disorders
08/24/2010US7781475 Oxindoles as kinase inhibitors
08/24/2010US7781474 Inhibitors of hepatitis C virus replication
08/24/2010US7781473 administering -Methyl-5-trifluoromethyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (4-cyano-3-trifluoromethyl-phenyl)-amide, for the treatment of benign prostatic hyperplasia, prostate carcinoma, hirsutism, alopecia, anorexia, breast cancer,acne, AIDS, cachexia or for male contraception
08/24/2010US7781472 overactive bladder; oxybutynin and pilocarpine are administered such that the peak saliva flow time point for pilocarpine occurs at nearly the same time as the lowest saliva flow time point for oxybutynin; reduced dry mouth side effect
08/24/2010US7781471 cannabinoid receptor antagonists, used for treating psychological disorders, neurodegenerative diseases, gastrointerstinal disorders, eating disorders, non-insulin dependent diabetes, drug abuse and dependence, headaches, obesity, sleep disorders and dyslipidemia
08/24/2010US7781470 Aminodicarboxylic acid derivatives having pharmaceutical properties
08/24/2010US7781469 peroxisome proliferator-activated receptor agonists, used for the treatment and/or prevention for hyperlipidemia, diabetes, obesity, arteriosclerosis, atherosclerosis, hyperglycemia and/or syndrome X.
08/24/2010US7781468 peroxisome proliferator-activated receptor (PPAR) agonists such as (2S)-3-{-4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)-ethoxy]-phenyl}-2-(3-phenyl-acryloylamino)-propionic acid, used for the treatment of hyperglycemia, dyslipidemia, non-insulin dependent diabetes and hyperlipemia
08/24/2010US7781465 Therapeutic oxazolidinones and thiazolidinones
08/24/2010US7781464 thiazolidin-2,4-diones or -oxazolidin-2,4-diones or thiones; obesity, inflammation, autoimmune diseases (multiple sclerosis, rheumatoid arthritis); increase the leptin level; no liver toxicity; inhibits TNF- alpha , IL-1, IL-6, IL-1 beta and cyclooxygenase COX-2; no affinity for PPAR-g; non-adipogenic.
08/24/2010US7781463 Enzyme inhibitors
08/24/2010US7781462 1-(3,4,5-trimethoxy-phenyl)-5-(4-bromo-phenyl)-1H-[1,2,3]triazole; 1-(2-hydroxy-4-methoxy-5-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-5-(4-bromo-phenyl)-1H-[1,2,3]triazole; inhibits tubulin polymerization in a cell; cancer
08/24/2010US7781461 Neuropeptide Y receptor antagonists comprising 4-(tert-butylsulfonylamino)-N-[5-(trifluoromethyl)pyridin-2-yl]cyclohexane-1-carboxamide and a pharmaceutically acceptable carrier, used for the treatment of obesity and as anorexigenic agents
08/24/2010US7781460 isoxazoline indazoles derivatives, such as 3-(1-Cyclopentyl-1H-indazol-6-yl)-5-methyl-4,5-dihydroisoxazole-5-carbonitrile, useful in the treatment of nervous system, respiratory system and skin disoders, AIDS, shock,, Crohn's disease, granuloma, vision defects and inflammatory diseases
08/24/2010US7781459 Carboxyalkoxy-substituted acyl-carboxyphenylurea derivatives and their use as medicaments
08/24/2010US7781458 Derivatives of pyridine and quinoline
08/24/2010US7781457 Isoquinolinone potassium channel inhibitors
08/24/2010US7781455 (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; dipeptidylpeptidase-IV enzyme inhibitors; diabetes
08/24/2010US7781454 Substituted indazoles, benzotriazoles, and related bicyclic compounds; HIV (human immunodeficiency virus) reverse transcriptase inhibitors; delays onset of AIDS or AIDS related complex
08/24/2010US7781453 Used as nitric oxide synthase inhibitors; treating acute inflammatory disease with such as 2-[2-(2-amino-4-methylpyridin-6-yl)ethyl]-3H-imidazo[4,5-b]pyridine
08/24/2010US7781452 such as 5-(4-Fluorophenoxy)-2-(((4-methoxy-3-methyl-2-pyridinyl)methyl)sulfinyl)-3H-imidazo[4,5-b]pyridine, useful as a gastric acid secretion inhibitor, for the treatment of gastroesophageal reflux or ulcers; antisecretory agents
08/24/2010US7781451 glucose kinase activators such as 3-Cyclopentyl-2-(4-ethoxymethanesulfonyl-phenyl)-N-(6-methoxy-thiazolo[5,4-b]pyridin-2-yl)-propionamide, enantiomorphs or mixtures, used for the treament of impaired glucose tolerance, non-insulin dependent diabetes and obesity in mammals
08/24/2010US7781450 protein kinase C or glycogen synthase kinase-3-beta inhibitors such as 3-(2-chlorophenyl)-4-[1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-1H-pyrrole-2,5-dione, used for treating cardiovascular, skin, nervous system disorders and immunological disorders, diabetes, inflammatory diseases and cancer
08/24/2010US7781449 Uniform blood concentration; sustained release; therapy for bladder disorders; FDA Orange book listed patent
08/24/2010US7781448 Once daily dosage forms of trospium
08/24/2010US7781447 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
08/24/2010US7781446 renal cancer; after standard chemotherapy; rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779)
08/24/2010US7781445 Synthesis of indenoisoquinoliniums and methods of use
08/24/2010US7781444 For local application to anus, of alpha-adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F2 alpha , dopamine, morphine, beta -blockers, and 5-hydroxytryptamine
08/24/2010US7781443 Tetrahydronaphthyridine derivatives and a process for preparing the same
08/24/2010US7781442 N-phenyl-1,3-thiazol-2-amine derivatives, useful in the treatment of neurodegenerative disorders, such as Alzheimer's disease
08/24/2010US7781441 (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amine
08/24/2010US7781440 Neurodegenerative diseases caused by GSK3 such as Alzheimer's disease
08/24/2010US7781439 such as 5-Chloro-6-(2,4-dichlorophenyl)-7-isopropylaminopyrazolo[1,5-a]pyrimidine-3-carboxylic acid, and optionally fungicides, bactericides, acaricides, nematocides and insecticides, used for controlling unwanted microorganisms
08/24/2010US7781438 Prevent transplant rejection
08/24/2010US7781437 chemokine receptor (CXCR3) antagonists, used for the treatment of inflammatory conditions, autoimmune disease, transplant rejection, infectious diseases, fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, diabetes, viral meningitis and tumors
08/24/2010US7781436 such as 1-Benzyl-2-methyl-1H-indol-3-yl)-(4-phenyl-piperidin-1-yl)-methanone, vasopressin (V1a) receptor antagonists, for the treatment of dysmenorrhea, hypertension, congestive heart failure, inappropriate secretion of vasopressin, cirrhosis, nephrosis, obsessive compulsive disorder and as anxiolytics